--- HOME ---

References

Awad, George A, and Lakshmi Voruganti, NP. (Winter, 1999) "Quality of Life and new antipsychotics in schizophrenia are patients better of?" The International Journal of Social Psychiatry. Vol. 45 i4 p268(7).

Bagnall A, Lewis RAS, Leitner ML and Kleijnen J. (2000) "Ziprasidone for schizophrenia and severe mental illness." Chochrane Database System Review. 2:CD001945.

Bernheim, Kayla F, and Lewine, Rachard RJ. (c.1979) "Schizophrenia. Symptoms, Causes, Treatments." George J. McLeod Limited, Toronto. (Publisher).

Capleton, RA (1996) Cognitive function in schizophrenia: Association with negative and positive symptoms. Psychol. Rep, 78; 123-128

Chen, EYH, Lam, LCW, Chen, RYL, Nguyen, DGH (1996) Negative symptoms, neurological signs and neuropsychological impairments in 204 Hong Kong Chinese patients with schizophrenia. Brit. J. Psychiatry, 168; 762-767

Docherty, NM, DeRosa, M, Andreasen, NC (1996) Communication disturbances in schizophrenia and mania. Arch. Gen. Psychiatry, 53; 358-364

Dossenbach, MR, Dratky P, Schineidman M, Grundy SL, Metcalfe S, Tollefson GD, and Belmaker RH. (2001) "Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone." Journal of Clinical Psychiatry. 62 Suppl 2:28-34.

Feldman, Robert S; Meyer, Jerrold S; and Quenzer, Linda F. (c. 1997) "Principles of Neuropsychopharmacology." Sinauer Associates Inc. (Publisher).

Gomez JC and Crawford AM. (2001) "Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial." Journal of Clinical Psychiatry.  62 Suppl 2:6-11.

Grinspoon, Lester, ed. New Treatments for Schizophrenia Part I. Harvard Mental

Harvard Health Publications Group. (1998) "New treatments for schizophrenia-Part I."  Harvard Mental Health Letter. Vol. 14 n10 p1(3).

Harvard Mental Health Letter. July 1997, 14(1). p 4(3).

Health Letter. April 1998, 14(10). p 1(3).Grinspoon, Lester, ed. New Treatments for Schizophrenia Part II. Harvard Mental

Health Letter. May 1998, 14(11). p 1(3).Hogarty, Gerald E. Cognitive Rehabilitation of Schizophrenia. Harvard Mental Health

Honey, Garry D.; Bullmore , Edward T.; Soni, William; Varatheesan, Malini; Williams, Steve CR; and Sharma, Tonmoy. (Nov, 1999) "Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia." Neurobiology. Vol. 96,i23 p 13432-13437.

Kinon BJ, Roychowdhury SM, Milton DR, and Hill AL. (2001) "Effective resolution with olanzapine of acute presentation of behavioral agitations and positive psychotic symptoms in schizophrenia." Journal of Clinical Psychiatry. 62 Suppl 2:17-21.

Kopelowicz, Alex; Zarate, Roberto; Tripodis, Konstantinos; Gonzalez, Veronica; and Mintz, Jim. (June 2000) "Differential Efficacy of Olanzapine for Deficit and Nondeficit Negative Symptoms in Schizophrenia." American Journal of Psychiatry. Vol. 157 i6 p98(7).

Kring, AM, Neale, JM (1996) Do schizophrenic patients show a disjunctive relationship among expressive, experiential, and psychophysiological components of emotion? Abnormal Psychology, 105(2), 249-257

Letter. August 2000, 17(2). p 4(3).

Lidow, Michael S. and Goldman. -Rakic, Patricia S. (May, 1994) "A common action of clozapine, haloperidol, and remoxipride on D1 and D2 dopaminergic receptors in the primate cerebral cortex."  Proceedings of the National Academy of Sciences. Vol. 91 p4353 -4356.

MedNET Web http://www.caregiver.org

Microsoft Encarta http://encarta.msn.com

Mueser, KT, Bellack, AS, Brady, EU (1990) Hallucinations in schizophrenia. Acta Psychiatr. Scandin., 82(1), 29-36

Mueser, KT, Doonan, R, Penn, DL, Blanchard, JJ, Bellack, AS, Nishith, P, DeLeon, J (1996) Emotion recognition and social competence in chronic schizophrenia. J Abnormal Psychology

Penn, DL, Corrigan, PW, Bentall, RP, Racenstein, JM, Newman, L. (1997) Research update on the psychosocial treatment of schizophrenia. Amer. J. Psychiatry, 153; 607-617

Perry PJ, Lund BC, Sanger T, and Beasley C. (Feb, 2001) "Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial." Journal of Clinical Psychopharmacology. Vol.21(1): 14-20.

Purdon, Scot E.; Jones, Barry DW; Stip, Emanuel; Labelle, Alan; Addington, Don; David, Stacy R; Breier, Alan; Tollefson, Gary D. (Mar 2000) "Neuropsychological Change in Early Phase Schizophrenia During 12 Months of Treatment with Olanzapine, Risperidone, or Haloperidol." Archives of General Psychiatry. Vol. 57 i3 p249.

Raaska K and Neuvonen PJ.(Nov, 2000)"Ciprfloxacin increases serum clozapine and N-desmethylclozapin: a study in patients with schizophrenia." European Journal of Clinical Pharmacology. Vol. 56(8): 585-9.

Radke, James M.; Owens, Michael J.; Ritchie, James C.; and Nemeroff, Charles B. (1998) "Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions." Neurobiology. Vol 95 i19 p11462-11464.

Sadock, Benjamin J. Comprehensive Textbook of Psychiatry. 7th ed. Lippincott

Wallis , Claudia and Willwerth, James. (July, 19992) "Schizophrenia: a new drug brings patients back to life." Time. V140 n1 p52(6).

Wiliams & Wilkins, Philadelphia; PA, 2000. Vol 1, p.1096 (135).

Wyatt, Richard Jed and Henter, Ioline D. Schizophrenia: The Need for Early Treatment.

Zhang XY, Zhou DF, Su JM, and Zhang PY. (Feb, 2001) "The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia."  Journal of Clinical Psychopharmacology. Vol. 21(1): 85-8.